Synbiotic: ProBioBaby®
AN INTEGRATED RESEARCH PLATEFORM
3 STRAINS
From in vivo and in vitro models showing synergy of the
strains…
2 Significant reductions in pro-inflammatory factors in both
models of infectionSynergistic impact of multi-strain combination
pathways
In vivo modulation of Th1 and Th2 immune responses10
• Th1 infection model: Wistar rats challengedwith
enterotoxigenic Escherichia coli (intracellular pathogen)
• Th2 challenge model: Wistar rats challengedwith
Nippostrongylus brasiliensis (extracellularpathogen)
IDENTIFICATION • Strain deposit: Collection Nationale de
Cultures de
Microorganismes, France- Lactobacillus helveticus Rosell®-52*
CNCM-I1722- Bifidobacterium infantis Rosell®-33CNCM-I3424-
Bifidobacterium bidifum Rosell®-71CNCM-I3426
• Origin: dairy
• 16S rRNA sequence confirms the species designation andthe
specific identity of our strains. The complete genome ofall three
strains have been sequenced and annotated
TNF-α (pg)/ml)
+
+
Control
N. brasiliensis
Rosell®-52
Rosell®-71
Rosell®-33
®
*
1401201000 20 40 60 80p
AN INTEGRATED RESEARCH PLATEFORM… to Clinical studies in
children
3
4
Spain• 220 healthy infants between 3 and
12 months old
• Randomized, double-blind, placebo-controlled, parallel-group,
intervention study
• 8 weeks supplementation,12 weeks monitoring
• 1 arm per strain and 1 placebo arm
• 135 school-aged children (3-6 years old)
• Healthy children who had suffered from at least three episodes
of Ears Nose & Throat (ENT),bronchopulmonary or gastric
disorder during the previous winter
• Placebo or ProBioBaby® once a day for 3 months
KEY PROBIOTIC FEATURES:• Demonstrated survival in GI tract
models (acidity, bile, dynamic model1, adhesion to epithelial
cells) and in human
• Robust documentation on modes of action for each strain:-
Rosell®-52 stimulates the immune system by increasing the number of
immune cells, activating B
cells and by acting on the production of cytokines2,3,4
- Rosell®-71 increases mucin expression in the small
intestine5
- All 3 strains have demonstrated pathogen inhibition
properties6,7
- Rosell®-52 surface-layer proteins, crystalline envelope of the
outer bacteria cell surface, allows L. helveticus Rosell®-52 to
have a strong adhesion capacity to intestinal epithelial cells and
to occupy the attachment sites of pathogenic bacteria such as E.
coli8
2 safety and tolerance studies in infants
China• 200 healthy infants between 4 and 6
months old
• Randomized, double-blind, placebo-controlled, parallel-group,
intervention study
• 4 weeks supplementation,14 weeks monitoring
• 2 arms: ProBioBaby® vs placebo
Cazzola et al. 201011: decreased incidence of infectious
episodes in children during winter
25% REDUCTION in the relative risk of infectious disease
(p=0.044) with Pro ® vs placebo
% of children with at least one adverse health event
Placebo
0 20 40 60 80
-25%
% of children with at least one lost day of school
Placebo
Probio ®
0 20 40 60 80
-40%
40% REDUCTION in the number of children who missed at least one
day of school because of an adverse health event (p=0.043) with Pro
® vs placebo
3
REFERENCES
ProBioBaby®
1. Tompkins TA. et al. (2011) The impact of meals on a probiotic
during transit through a model of the human upper gastrointestinal
tract. BeneficiaMicrobes. 2(4): 295-303 / 2. Easo JG. et al. (2002)
Immunostimulatory actions of Lactobacilli: Induction of antibody
production and spleen cell proliferation by Lactobacillus
delbrueckii subsp. bulgaricus and Lactobacillus acidophilus. Food
and agricultural immunology. 14: 73-83. / 3. Wallace TD. et al.
(2003) Interactions of lactic acid bacteria with human intestinal
epithelial cells: Effects on cytokine production. Journal of Food
Protection. 66 (3): 446-472. / 4. Easo et al (2002) Food &
Agricultural Immunology 14: 73-83. / 5. Dykstra N.S et al. (2011)
Pulse probiotic administration induces repeated small intestinal
Muc3 expression in rats. Pediatr. Res. 69(3): 206-11 / 6. Sherman
PM. et al. (2005) Probiotics reduce enterohemorrhagic Escherichia
coli 0157:H7- and enteropathogenic E. coli 0127:H6- induced changes
in polarized T84 epithelial cell monolayers by reducing bacterial
adhesion and cytoskeletal rearrangements. Infection and Immunity.
73 (8):5183-5188 / 7. Atassi F. et al. (2006) In vitro
antibacterial activity of Lactobacillus helveticus strain KS300
against diarrhoeagenic, uropathogenic and vaginosisassociated
bacteria. Journal of Applied Microbiology 101 (2006) 647–654 / 8.
Johnson-Henry KC. et al. (2006) Surface-layer protein extracts from
Lactobacillus helveticus inhibit entero-haemorrhagic Escherichia
coli O157:H7 adhesion to epithelial cells. Cellular Microbiology.
9(2): 356-367 / 9. Mac Pherson et al (2014) Multistrain Probiotic
Modulation of Intestinal Epithelial Cells’ Immune Response to a
Double-Stranded RNA Ligand, Poly(I·C), Applied and Environmental
Microbiology p. 1692–1700 March 2014 Volume 80 Number 5 / 10.
Cazzola M. et al. (2010a) Immunomodulatory impact of a symbiotic in
TH1 and TH2 modelsof infection. Ther Adv respir Dir. 4(5): 259-270
/ 11. Cazzola M. et al. (2010b) Efficacy of a synbiotic
supplementation in the prevention of common winter diseases in
children: a randomized, double-blind, placebo-controlled pilot
study. Ther Adv Respir Dis. 4(5), 271-278
FOR MORE INFORMATION, PLEASE CONTACT:
Lallemand Health Solutions Inc 17975 Rue des Gouverneurs,
Mirabel (Quebec) Canada J7 J2 J5`
[email protected]
www.lallemand-health-solutions.com
This is business-to-business information not intended for the
final consumer. It is based on our own research and development
work and is, to the best of our knowledge, reliable. However,
Lallemand does not assume any liability resulting from the use of
its products, as conditions of use are beyond our control. The
information provided should not be used as a substitute for any
form of advice and in all cases, producers and marketers should
check local regulatory requirements before use as different claims
may be made depending on the regulations applicable in each
country.
Unavia
- P
RO
202-
2016
03